Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Hays, J. T.    White, J. D.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation

A Randomized, Controlled Trial

J. Taylor Hays, MD; Richard D. Hurt, MD; Nancy A. Rigotti, MD; Raymond Niaura, PhD; David Gonzales, PhD; Michael J. Durcan, PhD; David P.L. Sachs, MD; Troy D. Wolter, MS; A. Sonia Buist, MD; J. Andrew Johnston, PhD; and Jonathan D. White, MS

18 September 2001 | Volume 135 Issue 6 | Pages 423-433

Background: Smoking relapse is common after successful pharmacologic treatment for smoking cessation. No previous studies have examined long-term drug therapy used expressly for prevention of smoking relapse.

Objective: To evaluate the efficacy of bupropion to prevent smoking relapse.

Design: Randomized, placebo-controlled trial.

Participants: 784 healthy community volunteers who were motivated to quit smoking and who smoked at least 15 cigarettes per day.

Intervention: The participants received open-label, sustained-release bupropion, 300 mg/d, for 7 weeks. Participants who were abstinent throughout week 7 of open-label treatment were randomly assigned to receive bupropion, 300 mg/d, or placebo for 45 weeks and were subsequently followed for an additional year after the conclusion of the medication phase. Participants were briefly counseled at all follow-up visits. At the end of open-label bupropion treatment, 461 of 784 participants (58.8%) were abstinent from smoking.

Measurement: Self-reported abstinence was confirmed by an expired air carbon monoxide concentration of 10 parts per million or less.

Results: The point prevalence of smoking abstinence was significantly higher in the bupropion group than in the placebo group at the end (week 52) of drug therapy (55.1% vs. 42.3%, respectively; P = 0.008) and at week 78 (47.7% vs. 37.7%; P = 0.034) but did not differ at the final (week 104) follow-up visit (41.6% vs. 40.0%). The median time to relapse was significantly greater for bupropion recipients than for placebo recipients (156 days vs. 65 days; P = 0.021). The continuous abstinence rate was higher in the bupropion group than in the placebo group at study week 24 (17 weeks after randomization) (52.3% vs. 42.3%; P = 0.037) but did not differ between groups after week 24. Weight gain was significantly less in the bupropion group than in the placebo group at study weeks 52 (3.8 kg vs. 5.6 kg; P = 0.002) and 104 (4.1 kg vs. 5.4 kg; P = 0.016).

Conclusions: In persons who stopped smoking with 7 weeks of bupropion treatment, sustained-release bupropion for 12 months delayed smoking relapse and resulted in less weight gain.

Author and Article Information

From the Mayo Clinic and Mayo Foundation, Rochester, Minnesota; Massachusetts General Hospital, Boston, Massachusetts; Brown University, Providence, Rhode Island; Oregon Health Science University, Portland, Oregon; Glaxo Wellcome, Inc., Research Triangle Park, North Carolina; Palo Alto Center for Pulmonary Disease Prevention, Palo Alto, California; and Stanford University School of Medicine, Stanford, California.

Acknowledgments: The authors thank Sue Wondrasch, Rhonda Baumberger, and JulieLynn Eckel for manuscript preparation.

Grant Support: By Glaxo Wellcome, Inc., Research Triangle Park, North Carolina.

Requests for Single Reprints: J. Taylor Hays, MD, Nicotine Research Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Current Author Addresses: Drs. Hays and Hurt: Nicotine Dependence Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Dr. Rigotti: General Internal Medicine, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, MA 02114.

Dr. Niaura: Center for Behavioral and Preventive Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906.

Dr. Gonzales: Smoking Cessation Center, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, CR 115, Portland, OR 97201.

Drs. Durcan and Johnston and Mr. White: Glaxo Wellcome, Inc., 5 Moore Drive, Research Triangle Park, NC 27709.

Dr. Sachs: Palo Alto Center for Pulmonary Disease Prevention, 145 North California Avenue, Palo Alto, CA 94301-3911.

Dr. Wolter: Section of Biostatistics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Dr. Buist: Division of Pulmonary and Critical Care, Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97201.

Author Contributions: Conception and design: R.D. Hurt, R. Niaura, D. Gonzales, M.J. Durcan, D.P.L. Sachs, J.A. Johnston.

Analysis and interpretation of the data: J.T. Hays, R.D. Hurt, N.A. Rigotti, R. Niaura, D. Gonzales, M.J. Durcan, D.P.L. Sachs, T.D. Wolter, A.S. Buist, J.A. Johnston, J.D. White.

Drafting of the article: J.T. Hays, R.D. Hurt, N. Rigotti, R. Niaura, D. Gonzales, M.J. Durcan, D.P.L. Sachs, T.D. Wolter, A.S. Buist, J.A. Johnston, and J.D. White.

Critical revision of the article for important intellectual content: J.T. Hays, R.D. Hurt, N.A. Rigotti, R. Niaura, D. Gonzales, M.J. Durcan, D.P.L. Sachs, T.D. Wolter, J.A. Johnston, J.D. White.

Final approval of the article: J.T. Hays, R.D. Hurt, N.A. Rigotti, R. Niaura, D. Gonzales, M.J. Durcan, T.D. Wolter, A.S. Buist, J.A. Johnston, J.D. White.

Provision of study materials or patients: J.T. Hays, N.A. Rigotti, R. Niaura, D. Gonzales, A.S. Buist, J.A. Johnston.

Statistical expertise: M.J. Durcan, T.D. Wolter, J.D. White.

Obtaining of funding: R.D. Hurt, M.J. Durcan, J.A. Johnston.

Administrative, technical, or logistic support: J.T. Hays, R.D. Hurt, D. Gonzales, M.J. Durcan, J.A. Johnston, J.D. White.

Collection and assembly of data: J.T. Hays, R.D. Hurt, N.A. Rigotti, R. Niaura, D. Gonzales, M.J. Durcan, D.P.L. Sachs, T.D. Wolter, A.S. Buist, J.A. Johnston, J.D. White.

Related articles in Annals:

Summaries for Patients
Bupropion To Prevent Relapse in People Who Quit Cigarette Smoking

Annals 2001 135: S40. [Full Text]  

This article has been cited by other articles:

				M. B. Steinberg, A. C. Schmelzer, D. L. Richardson, and J. Foulds The Case for Treating Tobacco Dependence as a Chronic Disease Ann Intern Med, April 1, 2008; 148(7): 554 - 556. [Abstract] [Full Text] [PDF]

				N. Rovina, I. Nikoloutsou, E. Dima, M. Michailidou, C. Roussos, and C. Gratziou Smoking cessation treatment in a real-life setting: the Greek experience Therapeutic Advances in Respiratory Disease, December 1, 2007; 1(2): 93 - 104. [Abstract] [PDF]

				B. Le Foll MD PhD and T. P. George MD Treatment of tobacco dependence: integrating recent progress into practice Can. Med. Assoc. J., November 20, 2007; 177(11): 1373 - 1380. [Abstract] [Full Text] [PDF]

				R. F. Leeman, C. J. Huffman, and S. S. O'Malley Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review Alcohol Alcohol., May 1, 2007; 42(3): 196 - 206. [Abstract] [Full Text] [PDF]

				P. Tonnesen, L. Carrozzi, K. O. Fagerstrom, C. Gratziou, C. Jimenez-Ruiz, S. Nardini, G. Viegi, C. Lazzaro, I. A. Campell, E. Dagli, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy Eur. Respir. J., February 1, 2007; 29(2): 390 - 417. [Abstract] [Full Text] [PDF]

				Varenicline (Chantix) for Tobacco Dependence Obstet. Gynecol., January 1, 2007; 109(1): 192 - 193. [Full Text] [PDF]

				S. A. Schroeder and H. C. Sox Trials that Matter: Varenicline: A Designer Drug to Help Smokers Quit. Ann Intern Med, November 21, 2006; 145(10): 784 - 785. [Full Text] [PDF]

				D. E. Jorenby, J. T. Hays, N. A. Rigotti, S. Azoulay, E. J. Watsky, K. E. Williams, C. B. Billing, J. Gong, K. R. Reeves, and for the Varenicline Phase 3 Study Group Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA, July 5, 2006; 296(1): 56 - 63. [Abstract] [Full Text] [PDF]

				S. Tonstad, P. Tonnesen, P. Hajek, K. E. Williams, C. B. Billing, K. R. Reeves, and for the Varenicline Phase 3 Study Group Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA, July 5, 2006; 296(1): 64 - 71. [Abstract] [Full Text] [PDF]

				T. Lancaster, P. Hajek, L. F. Stead, R. West, and M. J. Jarvis Prevention of Relapse After Quitting Smoking: A Systematic Review of Trials. Arch Intern Med, April 24, 2006; 166(8): 828 - 835. [Abstract] [Full Text] [PDF]

				D. P. L. Sachs Tobacco dependence treatment: time to change the paradigm. Chest, April 1, 2006; 129(4): 836 - 839. [Full Text] [PDF]

				W. H. Berrettini and C. E. Lerman Pharmacotherapy and Pharmacogenetics of Nicotine Dependence Am J Psychiatry, August 1, 2005; 162(8): 1441 - 1451. [Abstract] [Full Text] [PDF]

				S Holt, C Timu-Parata, S Ryder-Lewis, M Weatherall, and R Beasley Efficacy of bupropion in the indigenous Maori population in New Zealand Thorax, February 1, 2005; 60(2): 120 - 123. [Abstract] [Full Text] [PDF]

				C. Lerman, F. Patterson, and W. Berrettini Treating Tobacco Dependence: State of the Science and New Directions J. Clin. Oncol., January 10, 2005; 23(2): 311 - 323. [Abstract] [Full Text] [PDF]

				S. M. Hall, G. L. Humfleet, V. I. Reus, R. F. Munoz, and J. Cullen Extended Nortriptyline and Psychological Treatment for Cigarette Smoking Am J Psychiatry, November 1, 2004; 161(11): 2100 - 2107. [Abstract] [Full Text] [PDF]

				J. A. Simon, C. Duncan, T. P. Carmody, and E. S. Hudes Bupropion for Smoking Cessation: A Randomized Trial Arch Intern Med, September 13, 2004; 164(16): 1797 - 1803. [Abstract] [Full Text] [PDF]

				J S Haas, C P Kaplan, D Barenboim, P Jacob 3rd, and N L Benowitz Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use Tob. Control, March 1, 2004; 13(1): 52 - 56. [Abstract] [Full Text] [PDF]

				S Tonstad, C Farsang, G Klaene, K Lewis, A Manolis, A.P Perruchoud, C Silagy, P.I van Spiegel, C Astbury, A Hider, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study Eur. Heart J., May 2, 2003; 24(10): 946 - 955. [Abstract] [Full Text] [PDF]

				R. D. Hurt, J. E. Krook, I. T. Croghan, C. L. Loprinzi, J. A. Sloan, P. J. Novotny, C. G. Kardinal, J. A. Knost, M. T. Tirona, F. Addo, et al. Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking J. Clin. Oncol., March 1, 2003; 21(5): 914 - 920. [Abstract] [Full Text] [PDF]

				M. C. Fiore, D. K. Hatsukami, and T. B. Baker Effective Tobacco Dependence Treatment JAMA, October 9, 2002; 288(14): 1768 - 1771. [Full Text] [PDF]

				A. C. DeGraff Jr Pharmacologic Therapy for Nicotine Addiction Chest, August 1, 2002; 122(2): 392 - 394. [Full Text] [PDF]

				Can Bupropion Prevent Relapse After Smoking Cessation? Journal Watch Psychiatry, November 15, 2001; 2001(1115): 9 - 9. [Full Text]

				Can Bupropion Prevent Relapse After Smoking Cessation? Journal Watch (General), September 25, 2001; 2001(925): 2 - 2. [Full Text]